These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22386420)

  • 1. Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.
    Rhodes T; Jacobson DJ; McGree ME; St Sauver JL; Girman CJ; Lieber MM; Klee GG; Demissie K; Jacobsen SJ
    Urology; 2012 Mar; 79(3):655-61. PubMed ID: 22386420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
    Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
    Mikolajczyk SD; Rittenhouse HG
    Keio J Med; 2003 Jun; 52(2):86-91. PubMed ID: 12862359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study.
    Jacobsen SJ; Jacobson DJ; McGree ME; St Sauver JL; Klee GG; Girman CJ; Lieber MM
    Mayo Clin Proc; 2012 Jan; 87(1):34-40. PubMed ID: 22212966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.
    St Sauver JL; Jacobson DJ; Girman CJ; Lieber MM; McGree ME; Jacobsen SJ
    J Urol; 2006 Mar; 175(3 Pt 1):1018-22; discussion 1022. PubMed ID: 16469608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men.
    Rhodes T; Jacobson DJ; McGree ME; St Sauver JL; Sarma AV; Girman CJ; Lieber MM; Klee GG; Demissie K; Jacobsen SJ
    J Urol; 2012 Jan; 187(1):87-91. PubMed ID: 22093190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prostate health index selectively identifies clinically significant prostate cancer.
    Loeb S; Sanda MG; Broyles DL; Shin SS; Bangma CH; Wei JT; Partin AW; Klee GG; Slawin KM; Marks LS; van Schaik RH; Chan DW; Sokoll LJ; Cruz AB; Mizrahi IA; Catalona WJ
    J Urol; 2015 Apr; 193(4):1163-9. PubMed ID: 25463993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.
    Ito K; Fujizuka Y; Ishikura K; Cook B
    Int J Clin Oncol; 2014 Oct; 19(5):782-92. PubMed ID: 25135462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.
    Makarov DV; Isharwal S; Sokoll LJ; Landis P; Marlow C; Epstein JI; Partin AW; Carter HB; Veltri RW
    Clin Cancer Res; 2009 Dec; 15(23):7316-21. PubMed ID: 19934305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.
    Linton HJ; Marks LS; Millar LS; Knott CL; Rittenhouse HG; Mikolajczyk SD
    Clin Chem; 2003 Feb; 49(2):253-9. PubMed ID: 12560348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
    Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
    Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
    Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
    Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men.
    Rhodes T; Jacobson DJ; McGree ME; St Sauver JL; Sarma AV; Girman CJ; Lieber MM; Klee GG; Demissie K; Jacobsen SJ
    J Urol; 2012 Jan; 187(1):92-6. PubMed ID: 22093189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
    Tosoian JJ; Loeb S; Feng Z; Isharwal S; Landis P; Elliot DJ; Veltri R; Epstein JI; Partin AW; Carter HB; Trock B; Sokoll LJ
    J Urol; 2012 Oct; 188(4):1131-6. PubMed ID: 22901577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
    Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
    BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.